0001209191-19-005247.txt : 20190124 0001209191-19-005247.hdr.sgml : 20190124 20190124195137 ACCESSION NUMBER: 0001209191-19-005247 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190122 FILED AS OF DATE: 20190124 DATE AS OF CHANGE: 20190124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HILZINGER KURT J CENTRAL INDEX KEY: 0001191504 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37759 FILM NUMBER: 19541008 MAIL ADDRESS: STREET 1: 1300 MORRIS DRIVE STREET 2: SUITE 100 CITY: CHESTERBROOK STATE: PA ZIP: 19087 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Outlook Therapeutics, Inc. CENTRAL INDEX KEY: 0001649989 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 383982704 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 7 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: 6096193990 MAIL ADDRESS: STREET 1: 7 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER COMPANY: FORMER CONFORMED NAME: Oncobiologics, Inc. DATE OF NAME CHANGE: 20150804 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-01-22 0 0001649989 Outlook Therapeutics, Inc. OTLK 0001191504 HILZINGER KURT J C/O OUTLOOK THERAPEUTICS, INC. 7 CLARKE DRIVE CRANBURY NJ 08512 1 0 0 0 Common Stock 2019-01-22 4 P 0 10749 0.68 A 125196 D Common Stock 2019-01-23 4 P 0 2266 0.67 A 127462 D The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6605 - $0.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.66 - $0.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. /s/ Lawrence A. Kenyon, Attorney-in-Fact 2019-01-24